The psoriatic arthritis market was valued at USD 9.96 Billion in 2025, driven by the increasing prevalence of psoriatic arthritis and advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 9.50% during the forecast period of 2026-2035, with the values likely to reach USD 24.68 Billion by 2035.
Base Year
Historical Period
Forecast Period
The increasing prevalence of psoriatic arthritis and psoriasis is a primary driver of the market, propelling the demand for novel therapies and advanced treatment options.
The rise in drug approvals by regulatory agencies and increased investment in research and development (R&D) by pharmaceutical companies are expected to elevate the market value in the forecast period.
The rising advancements in oral small molecule therapies and the increase in the use of biologics are significant market trends.
Compound Annual Growth Rate
9.5%
Value in USD Billion
2026-2035
*this image is indicative*
Psoriatic arthritis (or PsA) refers to a chronic condition that is linked to joint pain, swelling, and stiffness along the bones that form the joints. It affects the individuals with the skin condition psoriasis. This form of arthritis is usually treated with the help of drugs, biologics, steroid injections, and joint replacement surgery. The rising prevalence of psoriatic arthritis and psoriasis is a primary driver of the market. The growing demand for biologic therapies such as TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors is expected to aid the market growth. Moreover, increased investment in research and development (R&D) by pharmaceutical companies and faster regulatory approvals for new psoriatic arthritis treatments are expected to shape the market dynamics.
Increasing Prevalence of Psoriatic Arthritis to Drive Market Growth
Recent data reveals that psoriatic arthritis occurs in around 20% of people affected by psoriasis, causing significant morbidity and reduced quality of life. The worldwide prevalence of psoriatic arthritis is estimated to be 112 per every 100,000 adults. Based on the population-based studies, the continent-specific estimates were reported to be 207 in Europe, 64 in North America, and 37 in Asia per 100,000 adults. The rising prevalence of psoriatic arthritis is a significant driver of the market, propelling the demand for novel therapies and advanced treatment options.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Market Breakup by Drug Class
Market Breakup by Form
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on Drug Class is Expected to Witness Substantial Growth
Based on the drug class, the market is segmented into NSAIDs, non-biologic disease modifying anti-rheumatic drugs (DMARDs), biologic disease modifying anti-rheumatic drugs (DMARDs), and others. Non-steroidal anti-inflammatory drugs (NSAIDs) are usually prescribed as a first-line treatment for mild to moderate psoriatic arthritis. They are effective for short-term use in managing acute symptoms as long-term use is often associated with potential side effects. On the other hand, non-biologic DMARDs help slow disease progression and prevent joint damage. These drugs work by interfering with various pathways involved in inflammation and immune response.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share, owing to the high prevalence of psoriasis and the presence of a well-developed healthcare system that offers comprehensive insurance coverage for specialty medications such as biologics and advanced therapies. The robust clinical trial activity and significant research and development (R&D) investments further support the market growth in the region. Moreover, the rising introduction of biologics and targeted small molecules is expected to fuel the market demand in the country.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Global pharmaceutical leader Pfizer is one of the key players in the market with a focus on developing innovative therapies across various therapeutic areas. Pfizer's oral JAK inhibitor XELJANZ/XELJANZ XR is used for the treatment of moderate to severe rheumatoid arthritis and active psoriatic arthritis in adults. The company is leveraging its strong global presence and extensive distribution network to reinforce its market position.
This American multinational medical devices and healthcare company has a prominent presence in the market. Humira (adalimumab) is the first fully human recombinant IgG1 monoclonal antibody developed by Abbott and it is widely used for treating psoriatic arthritis. The company is focused on expanding its portfolio with newer biologics and small molecules for the management of psoriatic arthritis to reduce reliance on Humira.
Pharmaceutical industry company GSK plc, headquartered in Brentford, United Kingdom, is a major market player with a robust portfolio of innovative treatments for autoimmune diseases including psoriatic arthritis. The company invests significantly in R&D to develop novel therapies for inflammatory diseases and establishes collaborations with biotech firms and research institutions to advance its pipeline.
Novartis AG, based in Basel, Switzerland, is an innovative medicines company offering innovative biologics and targeted therapies. The company's Cosentyx®(secukinumab) is indicated for the treatment of psoriatic arthritis. The medication is the first and only fully human biologic with the ability to directly inhibit interleukin-17A which is responsible for the inflammation in the disease.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Purdue Pharma LP, Sun Pharmaceutical Industries Limited, Eli Lilly and Company, Intas Pharma, Johnson & Johnson Services Inc., and Sanofi.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Form |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share